ADD ANI AS A TRUSTED SOURCE
googleads
Menu
Asia

SK Biopharm's new epilepsy medicine 'Cenobamate' to be released in Europe, firstly in Germany

Seoul [South Korea], June 16 (ANI/Global Economic): SK Biopharm's new epilepsy medicine 'Cenobamate' has been available in the European market.

ANI Jun 16, 2021 18:21 IST googleads

SK Biopharm's 'Cenobamate'. (SK Biopharm)

Seoul [South Korea], June 16 (ANI/Global Economic): SK Biopharm's new epilepsy medicine 'Cenobamate' has been available in the European market.
Angelini Pharma, a partner of SK Biopharm, announced on the 16th that it released Cenobamate for the first time in Germany earlier this month, under the product name 'ONTOZRY™'.
ONTOZRY was released locally in two months after it was approved by the European Commission (EC) in late March this year. On 4 June, it was also approved from the UK Medicines and Healthcare Products Regulatory Agency.
According to data from global research firm 'Decision Resources Group', there are currently an estimated 400,000 epilepsy patients in Germany.
SK Biopharm expects that if ONTOZRY's sales in Europe are expanded, it will be able to receive running royalties and milestones profits related to sales performance from Angelina Pharma.
Cenobamate is the epilepsy medicine developed by SK Biopharm. It was released in the US last year under the name "XCOPRI" and has been successfully sold, and entered the European market in a year.
Cenobamate is the first case that the new innovative medicine developed by Korean company was approved in Europe and entered European and US market.
Epilepsy is a central nervous system disorder that brain activity becomes abnormal and cause repeated seizures. (ANI/Global Economic)

Get the App

What to Read Next

US

Brazil’s Silveira rules out fuel shortages, slams speculation

Brazil’s Silveira rules out fuel shortages, slams speculation

Speaking to journalists, Silveira said the country's fuel supply remains stable and the government is closely monitoring developments in the international oil market as well as domestic price movements.

Read More
Asia

Policy delays leave Pakistan short of critical medicines

Policy delays leave Pakistan short of critical medicines

Pakistan faces a severe shortage of life-saving medicines, including cancer drugs and vaccines, due to government delays in notifying official prices. While global supply remains stable, regulatory hurdles have stalled legal imports, raising concerns over patient survival and the potential rise of unregulated, counterfeit medicines.

Read More
Europe

"Act of terrorism": Russia slams Mediterranean drone attack

Russian Foreign Ministry Spokesperson Maria Zakharova condemned a drone strike on the commercial vessel Arctic Metagaz in the Mediterranean. Calling it "a terrorist attack & a war crime," she detailed the crew's rescue after a gas explosion, criticised Malta's refusal to assist the injured, and denounced the European silence.

Read More
Asia

Pakistan’s outdated mandi system stifles agricultural innovation

Pakistan’s outdated mandi system stifles agricultural innovation

Pakistan's fruit and vegetable supply remains dominated by traditional middlemen and the "mandi" system, with digital platforms handling only 2-3% of trade. Restrictive provincial laws and lack of infrastructure force farmers into dependency on commission agents, stalling modern technological transformation in the agricultural sector.

Read More
Middle East

WHO says, "Public health risks are soaring"

WHO says,

The WHO has called on all parties to protect civilians and advocated that Peace remains the best medicine.

Read More
Home About Us Our Products Advertise Contact Us Terms & Condition Privacy Policy

Copyright © aninews.in | All Rights Reserved.